[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemostasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemostasis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,48,88,124,149,174,194,218,243,266],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054134","appropriateness-of-hemostatic-agent-use-in-cardiovascular-surgery-haemovax-100054134",false,"NCT07699016","Appropriateness of Hemostatic Agent Use in Cardiovascular Surgery (HAEMOVAX)","Evaluation of Appropriateness in the Use of Hemostatic Agents in Cardiovascular Surgery: A Mixed-Methods Single-Center Observational Study","HAEMOVAX","Inclusion Criteria:\n\n* Physicians with a surgical role in the Departments of Cardiac Surgery or Vascular Surgery at IRCCS Galeazzi-Sant'Ambrogio, Milan Including attending surgeons, consultant surgeons, and surgical residents\n* Active participation in cardiovascular operative procedures during the study period (or within the preceding 12 months)\n* Employment at the study institution at the time of survey administration Willingness to participate and complete the anonymous structured questionnaire\n\nExclusion Criteria:\n\n* Non-surgical healthcare personnel (e.g., nurses, anesthesiologists, administrative staff, or allied health professionals)\n* Surgeons not involved in operative cardiovascular practice during the study period\n* External collaborators or visiting surgeons without regular clinical activity at the institution\n* Individuals who do not provide informed consent for participation in the anonymous survey\n* Questionnaires with missing or incomplete vignette responses preventing calculation of the KPA-Score",true,"ALL","18 Years",{"count":21,"type":22},15,"ESTIMATED","OBSERVATIONAL","Hemostatic agents are widely used in cardiac and vascular surgery to support intraoperative bleeding control. Despite their clinical relevance and substantial economic impact, little is known about real-world patterns of use, adherence to evidence-based recommendations, and the alignment between clinicians' perceived knowledge and actual decision-making.\n\nHAEMOVAX is a single-center mixed-methods observational study conducted at IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. The study combines an anonymous survey of cardiovascular surgeons with a retrospective audit of institutional hemostatic agent consumption. The primary objective is to evaluate the appropriateness of hemostatic agent selection using a Knowledge-Practice Alignment Score (KPA-Score) derived from standardized clinical vignettes based on current EACTS and ESA recommendations. Secondary objectives include assessment of usage patterns, barriers to appropriate use, concordance between declared practice and real-world consumption, and opportunities for evidence-based standardization.",[26,27,28,29,30],"Hemostasis","Perioperative Bleeding","Cardiovascular Surgery","Cardiac Surgery","Vascular Surgery",[32,33,34,27],"Hemostatic Agents","Surgical Hemostasis","Topical Hemostatic Agents","RECRUITING","2026-07-07",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":22},"2026-07-01",{"date":43,"type":22},"2026-08-15",{"name":45,"class":46},"University of Milan","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":17,"sex":55,"minAge":19,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100620851","early-phase-1-topical-tranexamic-acid-to-reduce-blood-loss-during-cesarean-delivery-100620851","NCT07362992","Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery","Does Topical Use of Tranexamic Acid During a Cesarean Delivery Reduce Intra-surgical Bleeding? A Randomized ,Multi-center Trial","Inclusion Criteria:\n\n* Women aged 18 to 51 years\n* Singleton pregnancy\n* Elective cesarean delivery scheduled at ≥37+0 weeks of gestation\n* First or second cesarean delivery only\n* Low transverse uterine incision planned\n* Double-layer uterine closure using 1-0 Vicryl sutures\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to tranexamic acid (TXA)\n* History of bleeding or coagulation disorders\n* Previous postpartum hemorrhage\n* Placenta previa or placenta accreta spectrum\n* Presence of uterine myomas\n* Current use of anticoagulant or antiplatelet medications\n* Planned or intraoperative conversion to general anesthesia\n* Known uterine malformations\n* Known bleeding tendency or thromboembolic disease","FEMALE","51 Years",{"count":58,"type":22},112,"INTERVENTIONAL",[61],"EARLY_PHASE1","The goal of this clinical trial is to learn whether applying topical tranexamic acid (TXA) directly to the uterine incision during cesarean delivery can reduce surgical bleeding compared to placebo. The study will include pregnant women aged 18-51 undergoing elective cesarean delivery at term (37 weeks or more).\n\nThe main questions it aims to answer are:\n\n* Does topical TXA shorten uterine closure time?\n* Does topical TXA reduce the need for additional hemostatic sutures? Researchers will compare women receiving topical TXA to those receiving placebo (normal saline) to see if TXA reduces intraoperative bleeding and improves surgical outcomes.\n\nParticipants will:\n\n* Be randomly assigned to receive either topical TXA or placebo during cesarean delivery.\n* Have standard surgery and postoperative care identical in both groups.\n* Provide routine clinical data, including hemoglobin levels and recovery outcomes, from their medical records.",[64,65,66,26],"Cesarean Delivery","Postpartum Hemorrhage (PPH)","Intraoperative Blood Loss",[68,69,70,64,71,72,73,74,75,76,77,78],"Tranexamic Acid","Topical Tranexamic Acid","Hexakapron","Cesarean Section","Elective Cesarean","Postpartum Hemorrhage","Intraoperative Bleeding","Blood Loss Prevention","Uterine Closure","Randomized Controlled Trial","Maternal Outcomes",{"date":80,"type":39},"2026-07-02",{"date":41,"type":39},{"date":83,"type":22},"2028-12-31",{"name":85,"class":86},"Wolfson Medical Center","OTHER_GOV",4,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":94,"targetDuration":96,"studyType":23,"phases":4,"briefSummary":97,"conditions":98,"keywords":111,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":47},"100264360","investigation-of-the-genetics-of-hematologic-diseases-100264360","NCT02720679","Investigation of the Genetics of Hematologic Diseases","Inclusion Criteria:\n\n* An individual (proband) receiving therapy or expert consultation regarding a non-malignant hematologic disorder, MDS or MPN.\n* A biologically-related individual to the identified proband to include: first, second or third degree relatives.\n\nExclusion Criteria:\n\n* None",{"count":95,"type":22},1716,"10 Years","The purpose of this study is to collect and store samples and health information for current and future research to learn more about the causes and treatment of blood diseases. This is not a therapeutic or diagnostic protocol for clinical purposes. Blood, bone marrow, hair follicles, nail clippings, urine, saliva and buccal swabs, left over tissue, as well as health information will be used to study and learn about blood diseases by using genetic and\u002For genomic research. In general, genetic research studies specific genes of an individual; genomic research studies the complete genetic makeup of an individual.\n\nIt is not known why many people have blood diseases, because not all genes causing these diseases have been found. It is also not known why some people with the same disease are sicker than others, but this may be related to their genes. By studying the genomes in individuals with blood diseases and their family members, the investigators hope to learn more about how diseases develop and respond to treatment which may provide new and better ways to diagnose and treat blood diseases.\n\nPrimary Objective:\n\n* Establish a repository of DNA and cryopreserved blood cells with linked clinical information from individuals with non-malignant blood diseases and biologically-related family members, in conjunction with the existing St. Jude biorepository, to conduct genomic and functional studies to facilitate secondary objectives.\n\nSecondary Objectives:\n\n* Utilize next generation genomic sequencing technologies to Identify novel genetic alternations that associate with disease status in individuals with unexplained non-malignant blood diseases.\n* Use genomic approaches to identify modifier genes in individuals with defined monogenic non-malignant blood diseases.\n* Use genomic approaches to identify genetic variants associated with treatment outcomes and toxicities for individuals with non-malignant blood disease.\n* Use single cell genomics, transcriptomics, proteomics and metabolomics to investigate biomarkers for disease progression, sickle cell disease (SCD) pain events and the long-term cellular and molecular effects of hydroxyurea therapy.\n* Using longitudinal assessment of clinical and genetic, study the long-term outcomes and evolving genetic changes in non-malignant blood diseases.\n\nExploratory Objectives\n\n* Determine whether analysis of select patient-derived bone marrow hematopoietic progenitor\u002Fstem (HSPC) cells or induced pluripotent stem (iPS) cells can recapitulate genotype-phenotype relationships and provide insight into disease mechanisms.\n* Determine whether analysis of circulating mature blood cells and their progenitors from selected patients with suspected or proven genetic hematological disorders can recapitulate genotype-phenotype relationships and provide insight into disease mechanisms.",[99,100,101,26,102,103,104,105,106,107,108,109,110],"Bone Marrow Failure Syndromes","Erythrocyte Disorder","Leukocyte Disorder","Blood Coagulation Disorder","Sickle Cell Disease","Dyskeratosis Congenita","Diamond-Blackfan Anemia","Congenital Thrombocytopenia","Severe Congenital Neutropenia","Fanconi Anemia","Myelodysplastic Syndromes","Myeloproliferative Diseases",[112,113,114],"Genetics","Whole genome sequencing","Pediatrics and hematology","2026-06-05",{"date":117,"type":39},"2026-06-09",{"date":119,"type":39},"2016-06-17",{"date":121,"type":22},"2050-07",{"name":123,"class":46},"St. Jude Children's Research Hospital",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":18,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":59,"phases":134,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":148},"100567177","a-study-of-ethizia-versus-surgicel-original-in-controlling-soft-tissue-bleeding-during-open-surgery-100567177","NCT06664788","A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery","A Prospective, Multicenter, Randomized Clinical Investigation Evaluating the Safety and Efficacy of ETHIZIA™ Versus SURGICEL® Original in Controlling Minimal, Mild, or Moderate Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic, Thoracic (Non-cardiac) and Extremity Surgery","Inclusion Criteria:\n\nPre-operative\n\n* Participant is scheduled to undergo an elective open, abdominal, retroperitoneal, pelvic, thoracic (non-cardiac) or extremity surgical procedure\n* Participant is willing and able to give written informed consent for the clinical investigation participation\n\nIntra-operative\n\n* Participant in whom the Investigator can identify and visualize a target bleeding site for which any applicable conventional means for hemostasis (e.g., suture, ligature, or cautery) are ineffective or impractical\n* Target Bleeding Site is identified to originate from soft tissue, defined as organ bed, loose areolar tissue, fat, lymphatic tissue\u002Flymph node beds, and muscle\n* The choice is made to use a hemostatic agent to stop the bleeding, and there is the ability to apply pressure on the surface of the hemostatic agent to achieve hemostasis\n* Participant has a Target Bleeding Site with a SBSS score of 1, 2, or 3 (e.g., reflecting minimal, mild, or moderate bleeding severities)\n\nExclusion Criteria:\n\nPre-operative\n\n* Participant is scheduled for another planned surgery within the follow-up period and the subsequent surgery would jeopardize the ETHIZIA or SURGICEL Original application\n* Participant is taking multiple antithrombotic therapies in therapeutic dosage up to the time of surgery, but allowing exclusive use of acetylsalicylic acid\n* Participant has an active or suspected infection at the bleeding site\n* Participant is pregnant, planning on becoming pregnant, or actively breastfeeding during the 28-day follow-up period\n\nIntra-operative\n\n* Target bleeding site is identified to originate from parenchymal organ tissue, cardiovascular (anastomotic or cardiovascular repair sites) tissue, or is in proximity to a foramina in bone, or areas of bony confine\n* Target bleeding site is from a large defect in an artery or vein that requires vascular reconstruction with maintenance of vessel patency","22 Years",{"count":133,"type":22},108,[135],"NA","The objective of this clinical investigation is to evaluate the safety and efficacy of ETHIZIA to control minimal, mild, or moderate soft tissue bleeding during open surgery when compared to SURGICEL Original in the percentage of cases achieving hemostasis at 3 minutes after product application, and without re-bleeding up to 10 minutes after application.",[26,138],"Hemostatic Techniques","2026-06-04",{"date":115,"type":39},{"date":142,"type":39},"2025-04-16",{"date":144,"type":22},"2026-07-30",{"name":146,"class":147},"Ethicon, Inc.","INDUSTRY",7,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":59,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":47},"100614409","safety-and-effectiveness-of-the-vascular-closure-device-for-femoral-artery-hemostasis-in-patients-of-femoral-artery-puncture-100614409","NCT07279220","Safety and Effectiveness of the Vascular Closure Device for Femoral Artery Hemostasis in Patients of Femoral Artery Puncture","A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Safety and Effectiveness of the Vascular Closure Device for Femoral Artery Hemostasis in Patients of Femoral Artery Puncture","Inclusion Criteria:\n\n1. Age 18\\~80, male or non-pregnant female;\n2. Subjects undergoing interventional diagnostic or therapeutic procedures via femoral artery puncture;\n3. Subjects using 5F to 8F sheaths during the procedure (Note: Subjects using 5F-7F sheaths will enter the main randomized controlled cohort, while subjects using 8F sheaths will directly enter the single-arm observational cohort);\n4. Subjects or their legally authorized representatives can understand the purpose of the trial, voluntarily participate in the trial and sign informed consent form, and be able and willing to comply with follow-ups and related procedures.\n\nExclusion Criteria:\n\n1. Subjects with femoral artery occlusion or visually estimated lumen diameter \\\u003C5mm;\n2. Subjects with prior surgical procedures, percutaneous transluminal angioplasty (PTA), stent placement, or vascular grafts at the access site;\n3. Subjects with visible calcification at the access site, clinically significant peripheral vascular disease (requiring intervention), or stent implantation ≤1cm from the puncture site;\n4. Subjects whose puncture site is above the lowest edge of the inferior epigastric artery and\u002For above the inguinal ligament as identified by skeletal markers;\n5. Subjects with posterior wall vascular puncture or multiple femoral artery punctures due to difficulty in obtaining vascular access;\n6. Patients with pathological obesity (BMI \\>40 kg\u002Fm²);\n7. Subjects with pre-existing access site complications (hematoma, pseudoaneurysm, arteriovenous fistula, dissection, etc) or any procedure-related complications that may affect recovery, ambulation, or discharge timing;\n8. Subjects with acute ST-segment elevation myocardial infarction within 48 hours prior to the procedure;\n9. Subjects with uncontrolled hypertension during closure (Systolic BP \\>180 mmHg or Diastolic BP \\>110 mmHg);\n10. Subjects who are known to be contraindicated or allergic to iodine-containing contrast agents or polyethylene glycol materials;\n11. Subjects with severe thrombocytopenia (Platelet count \\\u003C30×10⁹\u002FL), hemophilia, von Willebrand disease, or severe anemia (Hemoglobin \\\u003C10 g\u002FdL, Hematocrit \\\u003C30%);\n12. International normalized ratio (INR) \\>1.5;\n13. Subjects with systemic infection or skin infection at the puncture site, or planned indwelling sheath;\n14. Subjects unable to ambulate 6 meters without assistance;\n15. Pregnant or lactating women;\n16. Subjects currently participating in other drug\u002Fdevice clinical trials;\n17. Other subjects deemed ineligible for this clinical trial by the investigator.","80 Years",{"count":158,"type":22},238,[135],"The purpose of this study is to verify the safety and effectiveness of the Vascular Closure Device manufactured by Shanghai Bomaian Medical Technology Co., Ltd. for femoral artery hemostasis in patients of femoral artery puncture.",[162,163,26],"Femoral Artery Puncture","Vascular Closure Device","NOT_YET_RECRUITING","2025-11-30",{"date":167,"type":39},"2025-12-12",{"date":169,"type":22},"2025-12-29",{"date":171,"type":22},"2026-05-15",{"name":173,"class":147},"Shanghai Bomaian Medical Technology Co., Ltd",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":47},"100574019","choice-of-anticoagulant-for-primary-hemostasis-studies-with-pfa200-platelet-function-analyser-100574019","NCT06753838","Choice of Anticoagulant for Primary Hemostasis Studies With PFA200® (Platelet Function Analyser)","BAPAPFA","Inclusion Criteria:\n\n* Person having given their non-opposition\n* Person of legal age\n* Person receiving a haemostasis consultation at the haemophilia and haemorrhagic diseases treatment center followed by a blood sample with a PFA test prescribed by the doctor (the test is not added for the study).\n\nExclusion Criteria:\n\n* persons under legal protection (curatorship, guardianship)\n* persons subject to a court protection order\n* pregnant, parturient or breast-feeding women\n* adult incapable or unable to give consent\n* minor",{"count":182,"type":22},100,"The PFA (platelet function analysis) test is prescribed for the exploration of primary hemostasis and the study of platelet-willebrand factor interaction. It is performed using citrated blood, with technical difficulties and frequent alarms that may be linked to the choice of anticoagulant (citrate). It is proposed to compare the results obtained with a conventional citrate tube and a BAPA tube, which is an anticoagulant used in clinical research and which blocks coagulation by another mechanism that would have less impact on blood platelets.",[26],"2025-09-26",{"date":187,"type":39},"2025-09-29",{"date":189,"type":39},"2025-01-21",{"date":191,"type":22},"2025-12",{"name":193,"class":46},"Centre Hospitalier Universitaire Dijon",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":202,"conditions":203,"keywords":206,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":47},"100391477","thrombo-embolic-events-in-hospitalized-patients-with-covid-19-serious-acute-pneumopathy-100391477","NCT04377490","Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy","THROMBCOVID2","Inclusion Criteria:\n\n* all patients hospitalized in Amiens Hospital with COVID-19 infection\n\nExclusion Criteria:\n\n* patients\\\u003C 18 years",{"count":182,"type":22},"The understanding of haemostasis and inflammation cross-talk has gained considerable knowledge during the past decade in the field of arterial and venous thrombosis. Complex and delicately balanced interaction between coagulation and inflammation involve all cellular and humoral components.\n\nElements of the coagulation system such as activated thrombin, fibrinogen or factor Xa may increase inflammation by promoting the production of proinflammatory cytokines, chemokines, growth factors and adhesion molecules that lead to a procoagulant state amplifying the pathological process. Recent evidence supports inflammation as a common pathogenic contributor to both arterial and venous thrombosis, giving rise to the concept of inflammation induced thrombosis.\n\nPatients with infection of COVID-19 and severe pneumoniae seem to have higher risk of thromboembolism. The purpose of this project is to analyze hemostasis and coagulation of every hospitalized patient with infection of COVID-19.\n\nBlood sample for coagulation and hemostasis analysis will be collected on every patient hospitalized in Amiens hospital for COVID-19 infection. Thrombin time, factors V and II, fibrin\u002Ffibrinogen degradation products, antithrombin will be assessed every week. Anticardiolipin, anti-beta2 glycoprotein I and anti-annexin A2 antibodies IgG and IgM at day of admission and at fourth week after admission will be assessed. SARS-CoV2 viral load and serodiagnosis will be performed at the same time. At the same time venous ultrasound to diagnose thrombosis will be performed.",[204,26,205],"COVID-19","Coagulation",[204,207,26,208],"venous ultrasound","coagulation","2025-05-23",{"date":211,"type":39},"2025-05-29",{"date":213,"type":39},"2020-05-04",{"date":215,"type":22},"2025-11",{"name":217,"class":46},"Centre Hospitalier Universitaire, Amiens",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":59,"phases":228,"briefSummary":229,"conditions":230,"keywords":233,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":47},"100587877","ultrasound-of-the-spleen-utilizing-low-energy-diagnostic-level-insonification-100587877","NCT06934096","Ultrasound of the Spleen Utilizing Low-energy (Diagnostic Level) Insonification.","Effects of Ultrasound Insonification of the Spleen on Platelet Activity and Coagulation Biomarkers in Healthy Human Subjects","Inclusion Criteria\n\n1. Provision of signed and dated informed consent form\n2. Willingness to comply with all study procedures and availability for the entire study duration\n3. Male or female, aged 18 to 50 years\n4. Individuals without physical disabilities or conditions\u002Fdiseases that may make them incapable of undergoing the study procedure or otherwise places them at a greater risk of harm.\n5. Individuals without significant past medical or surgical histories that would render them at a greater risk of harm\n6. Individuals that are considered English Proficient due to the study requirements to follow verbal commands during the ultrasound session\n7. Individuals that are considered active as assessed by type of activity (i.e., walking, running, etc.) and number of hours a week performing the various activities\n8. Willing to adhere to the ultrasound study regimen\n9. Individuals able to attend all study visits at approximately the same time of day (i.e., 8-12 pm)\n10. Individuals able to comprehend the study goals and procedures, and can provide informed consent for participation\n\nExclusion Criteria:\n\n1. Individuals participating in another research study that may affect the conduct or results of this study\n2. Individuals considered substantially overweight or obese via body mass index (BMI \\> 30)\n3. Individuals having or exhibiting any of the following:\n\n   * surgery in the past 90 days\n   * previous surgery of the spleen or splenectomy, esophagus, lungs, stomach, duodenum, or liver\n   * recent traumatic injury, including intracerebral hemorrhage and visceral injury\n   * end stage renal disease and\u002For uremia\n   * active malignancy\n   * previous leukemia and\u002For lymphoma\n   * human immunodeficiency virus infection or AIDS\n   * rheumatoid arthritis or other immune-mediated diseases (e.g. inflammatory bowel disease)\n   * arrhythmias, including but not limited to, atrial fibrillation, atrial flutter, clinically significant bradycardia, ventricular arrhythmias, and A-V block\n   * implanted pacemaker or cardioverter\u002Fdefibrillator (AICD)\n   * history of stable or unstable angina, myocardial infarction, angioplasty, or coronary arterial by-pass grafting surgery\n   * history of stroke or TIA\n   * history of deep venous thrombosis (DVT) and\u002For pulmonary embolism (PE)\n   * previous episodes of pancreatitis\n   * spinal disorders\n   * chronic pain syndromes\n   * stage III-IV pressure ulcers\n   * sickle cell anemia or other anemia syndromes\n   * diagnosed with fever of unknown origin (FUO)\n   * previously or currently implanted vagus nerve stimulator\n   * previously or currently implanted spinal cord stimulator or other chronically implanted electronic medical device\n   * history of seizures\n   * history of cancer\n4. Individuals who have taken any of the following medications within two weeks of receiving ultrasound delivery:\n\n   * anti-coagulants (warfarin, Xarelto)\n   * anti-platelet agent (aspirin, clopidogrel)\n   * anti-inflammatory (aspirin, NSAIDs)\n   * anti-hypertensive (α-methyldopa)\n   * epinephrine-related drugs, norepinephrine-related drugs, and drugs that stimulate release of epinephrine and\u002For norepinephrine (Micronefrin, Asthmanefrin)\n   * immunosuppressive agents (steroids, newer immunomodulatory drugs)\n   * alpha and\u002For beta-adrenoceptor blocking agents\n   * anti-seizure medications\n   * other medications, supplements, etc. that may interfere with the ultrasound delivery or study results\n5. Individuals with a substance abuse (alcoholism or other) problem\n6. Individuals that consumed alcohol within 7 days of the baseline visit\n7. Individuals currently using or have used cocaine, heroin, marijuana, or other illicit recreational drugs within the past 3 months\n8. Prisoners\n9. Participant has a history of thrombocytopenia (platelet count \\\u003C100k)\n10. Participant has reported coagulopathy (elevated PT, PTT, elevated activated clotting time (ACT))\n11. Participant has internal bleeding, external bleeding, easy bruising\n12. Participant has a history of abnormal bleeding or blood disorder, including anemia or anemia-related disorders\n13. Participant has a history of thrombocytopenia (platelet count \\\u003C100k)\n14. Participant has a history of coagulopathy, including hemophilia, stroke, pulmonary embolism, myocardial infarction, or deep vein thromboses\n15. Participant has a history of conditions that can cause coagulopathic conditions, including atrial fibrillation, heart valve surgery or replacement, hip or knee replacement, or clotting disorders\n16. Participants using coagulation- or platelet-modifying therapies such as clotting factor products, emicizumab, desmopressin acetate, epsilon amino caproic acid, heparin and its derivatives, argatroban, desirudin, bivalirudin, dabigatran, apixaban, edoxaban, betrixaban\n17. Participant has a history of chronic tobacco use or has ingested nicotine via smoking, vaping, smokeless tobacco, or nicotine patches in the past three months\n18. Participant has consumed caffeine within the past 12 hours\n19. Participant has received a blood transfusion within 30 days prior to study\n20. Participant has a history of neurologic diseases or traumatic brain injury\n21. Women of childbearing potential, not using adequate contraception as per investigator judgment or not willing to comply with contraception for the duration of the study\n22. Females who are pregnant, lactating or menstruating\n23. Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants are risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial","50 Years",{"count":227,"type":22},39,[135],"This is a three-cohort, randomized, double-blinded , sham-controlled, single-center, early feasibility research trial to determine whether organ-specific biologic effects on platelet activity and coagulation are achievable through selective ultrasound of the spleen utilizing low-energy (diagnostic-level) insonification.\n\n* Group 1: Focused insonification at center of the spleen.\n* Group 2: Prolonged duration insonification at center of the spleen\n* Group 3: Prolonged duration insonification across the spleen.\n\nParticipants will receive 30 minutes of sham stimulation in the randomized group that is assigned to them, followed by active stimulation within the same group. Blood biomarkers (local and systemic) will be measured before and at several timepoints after stimulation to measure the molecular and cellular effects of the device",[26,231,232],"Blood Biomarkers","Ultrasound",[234],"Ultrasound of the spleen",{"date":236,"type":39},"2025-04-18",{"date":238,"type":22},"2025-04-15",{"date":240,"type":22},"2026-05-12",{"name":242,"class":46},"Northwell Health",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":59,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":265},"100522139","vascular-closure-with-a-device-compared-to-manual-compression-after-atrial-fibrillation-ablation-the-locket-ii-study-100522139","NCT06078735","Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study","Vascular Closure With Novel Ergonomic External Compression Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study","Inclusion Criteria:\n\n* Must be at least 18 years of age\n* Be able to provide consent\n* Presenting for planned procedures that require percutaneous venous punctures, such as atrial fibrillation radiofrequency ablation, and where the physician utilizes a LockeT device or MC to close the wound.\n\nExclusion Criteria:\n\n* Under the age of 18\n* Unable to or unwilling to provide consent\n* Cannot comply with study requirements\n* Not undergoing procedures that require a percutaneous venous puncture or planned access to the left atrium and\u002For ventricle\n* Subjects whose physician does not use LockeT or MC to close the venous puncture.\n* Patient is currently pregnant, as evidenced by positive urine Beta-HCG. (Urine Beta Human chorionic gonadotropin (HCG) will be checked in all females of the reproductive age group).\n* If the physician detects a formed hematoma prior to venous closure, that patient will be excluded from the study.",{"count":251,"type":22},110,[135],"The LockeT II study is a single center, prospective randomized study. It is intended to study the effectiveness of using LockeT device to gain hemostasis after venous procedures as compared to Manual Compression (MC). Approximately 110 patients will be enrolled.",[255,26],"Atrial Fibrillation","2024-10-25",{"date":258,"type":39},"2024-10-29",{"date":260,"type":39},"2023-10-02",{"date":262,"type":22},"2024-12",{"name":264,"class":46},"Kansas City Heart Rhythm Research Foundation",6,{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":156,"enrollmentInfo":274,"targetDuration":4,"studyType":59,"phases":276,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":291,"locationsCount":293},"100500003","effect-of-patent-hemostatic-device-phd-with-quantitative-pressure-on-radial-artery-hemostasis-after-cagpci-100500003","NCT05790603","Effect of Patent Hemostatic Device (PHD) With Quantitative Pressure on Radial Artery Hemostasis After CAG\u002FPCI","Effect of Patent Hemostatic Device (PHD) With Quantitative Pressure on Radial Artery Hemostasis After CAG\u002FPCI：a Randomized Controlled Trial","PCI","Inclusion Criteria:\n\nPatients undergoing coronary angiography or percutaneous coronary intervention via the radial artery; Positive Allen's test result; Willing to sign informed consent.\n\nExclusion Criteria:\n\nRadial artery malformation； Chronic kidney disease with eGFR\\\u003C30ml\u002Fmin.1.73m2; Cirrhosis of the liver; Coagulation disfunction; Patients treated with IIb \u002F IIIa receptor antagonist.",{"count":275,"type":22},200,[135],"The objective of this clinical trial is to compare the hemostatic effect of 2 hemostatic devices with or without quantitative pressure on radial arteries after coronary angiography (CAG) or percutaneous coronary intervention (PCI). The main questions aims to answer:\n\n* What is the hemostatic effect of the patent hemostatic device with quantitative pressure after percutaneous coronary intervention?\n* What are the precise hemostatic pressure and hemostatic time of the radial artery after CAG\u002FPCI? Participants will be randomly assigned to the intervention group (IG) and control group (CG). The IG will use patent hemostatic device with quantitative pressure (PHDQP-Band, China) while the CG will use the conventional radial artery hemostatic device (TR-Band, Japan) without pressure monitoring.\n\nThe primary outcomes is incidence of 24h radial artery occlusion (24h RAO). Secondary outcomes include time to hemostasis, bleeding, hematoma, 30d radial artery occlusion (30d RAO), pain, hand swelling, numberness, pseudoaneurysm, and radial artery stenosis.",[279,26],"Percutaneous Coronary Intervention",[281,282,283,284],"Percutaneous coronary intervention","Radial artery hemostasis","Quantitative pressure","Randomized controlled trial","2024-07-09",{"date":287,"type":39},"2024-07-11",{"date":289,"type":39},"2024-05-21",{"date":262,"type":22},{"name":292,"class":46},"Peking University First Hospital",2]